BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8761020)

  • 1. V2-receptor blockade enhances pressor response to vasopressin: gender difference.
    Wang YX; Crofton JT; Liu H; Sato K; Share L
    Life Sci; 1996; 59(8):695-703. PubMed ID: 8761020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central vasopressin blockade enhances its peripheral release in response to peripheral osmotic stimulation in conscious rats.
    Liu HW; Wang YX; Crofton JT; Funyu T; Share L
    Brain Res; 1996 May; 719(1-2):14-22. PubMed ID: 8782858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasopressin V2 receptor enhances gain of baroreflex in conscious spontaneously hypertensive rats.
    Sampey DB; Burrell LM; Widdop RE
    Am J Physiol; 1999 Mar; 276(3):R872-9. PubMed ID: 10070150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of vasopressin on cardiovascular changes during hemorrhage in conscious rats.
    Fujisawa Y; Miyatake A; Hayashida Y; Aki Y; Kimura S; Tamaki T; Abe Y
    Am J Physiol; 1994 Nov; 267(5 Pt 2):H1713-8. PubMed ID: 7977803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced pressor response in spontaneously hypertensive rats induced by stimulation of vasopressin-V1 receptors.
    Yamauchi T; Ogura T; Oishi T; Harada K; Hashimoto M; Mimura Y; Asano N; Ota Z; Kageyama J
    Acta Med Okayama; 1995 Feb; 49(1):53-9. PubMed ID: 7762410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular responses to vasopressin antagonists in man and rat.
    Burrell LM; Phillips PA; Rolls KA; Buxton BF; Johnston CI; Liu JJ
    Clin Sci (Lond); 1994 Oct; 87(4):389-95. PubMed ID: 7834989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baroreflex buffering of pressor response to vasopressin is mediated by V1, not V2, receptors in conscious rats.
    Shimizu K; Schwartz J; McGrath BP
    Am J Physiol; 1993 Feb; 264(2 Pt 2):R345-9. PubMed ID: 8447490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arginine vasopressin produces renal vasodilation via V2 receptors in conscious dogs.
    Naitoh M; Suzuki H; Murakami M; Matsumoto A; Ichihara A; Nakamoto H; Yamamura Y; Saruta T
    Am J Physiol; 1993 Oct; 265(4 Pt 2):R934-42. PubMed ID: 8238468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular and renal effects of vasopressin and its antagonists in conscious rats with chronic myocardial infarction; evidence for receptor shift.
    Lankhuizen IM; van Veghel R; Saxena PR; Schoemaker RG
    Eur J Pharmacol; 2001 Jul; 423(2-3):195-202. PubMed ID: 11448485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of vasopressin V1 and V2 receptor antagonists on the development of salt-induced hypertension in Dahl rats.
    Hashimoto J; Imai Y; Minami N; Munakata M; Abe K
    J Cardiovasc Pharmacol; 1995 Oct; 26(4):548-54. PubMed ID: 8569214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of nonpeptide vasopressin V2 antagonist OPC-31260 in heart failure in the rat.
    Burrell LM; Phillips PA; Risvanis J; Chan RK; Aldred KL; Johnston CI
    Am J Physiol; 1998 Jul; 275(1):H176-82. PubMed ID: 9688911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of vasopressin V1- and V2-receptor stimulation on blood pressure in DOCA-salt hypertensive rats.
    Mimura Y; Ogura T; Yamauchi T; Otsuka F; Oishi T; Harada K; Hashimoto M; Ota Z
    Acta Med Okayama; 1995 Aug; 49(4):187-94. PubMed ID: 7502678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of vasopressin V (OPC-21268) and V2 (OPC-31260) antagonists on renal hemodynamics and excretory function.
    Nakamura T; Sakamaki T; Kurashina T; Hoshino J; Sato K; Ono Z; Murata K
    Life Sci; 1994; 55(4):PL67-72. PubMed ID: 8028441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sexual dimorphism in regional blood flow responses to vasopressin in conscious rats.
    Wang YX; Crofton JT; Bealer SL; Share L
    Am J Physiol; 1997 Sep; 273(3 Pt 2):R1126-31. PubMed ID: 9321895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of long-term treatment with selective vasopressin V1 and V2 receptor antagonist on the development of heart failure in rats.
    Nishikimi T; Kawano Y; Saito Y; Matsuoka H
    J Cardiovasc Pharmacol; 1996 Feb; 27(2):275-82. PubMed ID: 8720428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidiuretic effects of a nonpeptide vasopressin V(2)-receptor agonist, OPC-51803, administered orally to rats.
    Nakamura S; Hirano T; Tsujimae K; Aoyama M; Kondo K; Yamamura Y; Mori T; Tominaga M
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1005-11. PubMed ID: 11082435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of vasopressin in neurocardiogenic responses to hemorrhage in conscious rats.
    Imai Y; Kim CY; Hashimoto J; Minami N; Munakata M; Abe K
    Hypertension; 1996 Jan; 27(1):136-43. PubMed ID: 8591876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of gonadectomy on sexually dimorphic antidiuretic action of vasopressin in conscious rats.
    Wang YX; Crofton JT; Liu H; Brooks DP; Share L
    Am J Physiol; 1994 Aug; 267(2 Pt 2):R536-41. PubMed ID: 8067465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of vasopressin on arterial blood pressure and cardiac output in male and female rats.
    Toba K; Crofton JT; Inoue M; Share L
    Am J Physiol; 1991 Nov; 261(5 Pt 2):R1118-25. PubMed ID: 1951759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitric oxide may participate in V2 vasopressin-receptor-mediated renal vasodilation.
    Aki Y; Tamaki T; Kiyomoto H; He H; Yoshida H; Iwao H; Abe Y
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):331-6. PubMed ID: 7511766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.